Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: API Import to Russia (August 2017)

Friday, September 29, 2017

Between January and August 2017, Russia imported 48.9 bln RUB worth of APIs (free circulation prices, VAT included). Pharmacopoeial APIs account for most of the import (97.4%). The import has risen by 28% in monetary terms, with pharmacopoeial APIs contributing the most. The import of pharmacopoeial APIs has increased by 29%, while the import of technical APIs decreased by 2.4%.

In physical terms, the total dynamics are 9.9%, with the dynamics of pharmacopoeial and technical APIs being 9.7% and 15.7%, respectively. The total import in physical terms is around 8.02 tons of APIs.

China is the leader in the import in physical terms, with 19.7% of the import, and the import line, with 336 API names.

Ireland has made the best progress, with a nearly 600 times increase. While Russia imports only 3 API names from Ireland, nearly 95% of the import in monetary terms accounts for antigens for vaccine production for the prevention of pneumococcal infections.

Read more about API import to Russia (Q1 – Q2 2017) here:

Tab 1. Top 15 countries manufacturing API (including technical APIs) with the largest import to Russia (January – August 2017), in monetary terms